The development of new, more effective targeted therapies has led to an increase in our understanding of cell signaling pathways associated with ovarian carcinogenesis and progression. Further studies will be needed to develop methods of assessing response to these agents and their potential role in the management of ovarian cancer.
Ovarian carcinoma can be cured; however, there may be long-term side effects from adjuvant chemotherapy. Ovarian epithelial carcinomas can be cured with surgery. There may be long-term side effects from adjuvant chemotherapy.
The overall risk of developing carcinoma was 2%, and there was no significant difference between women who had a BRCA mutation and those without a mutation. Women who did not develop [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) were at an increased risk of developing a second primary cancer, particularly ovarian epithelial cancer (EOC), but this risk was not significantly different from the risk found in women without a BRCA mutation.
There was a significant decreasing trend in the age at diagnosis from 1980 to 2003. This suggests that cancer control programs should focus on younger patients.
There has been little information on the usual characteristics of XB002 responders in women with advanced ovarian cancer. This preliminary analysis suggests that a majority of XB002 responders exhibit no specific histological features suggestive of current chemotherapy response. Further investigation into the heterogeneity of ovarian cancer phenotype is warranted before conclusions regarding treatment response can be made.
These data suggest that the safety profile of xb002 is comparable to that of previously investigated drugs in this class, including antiangiogenic drugs (bevacizumab, sorafenib, sunitinib, etc.) The fact that no major grade 3 or 4 toxicities were observed In a recent study suggests that xb002 has a favorable safety profile compared to these previous agents, as well.
The addition of Xb002 to chemotherapy increased time to progression and improved overall survival compared with chemotherapy alone in a cohort of patients with epithelial ovarian cancer.
Ovarian cancer is highly aggressive and tends to recur within 1 year after surgical resection in most cases. It is therefore imperative that patients have regular screening to detect early recurrence. Patients should be encouraged to have their ovaries removed if they develop fertility problems during their disease course.
The prevalence of carcinoma, ovarian epithelium is relatively low in the US population, despite the high incidence of this disease. Most cases occur in developed countries.
The 5-year survival rate for serous epithelial ovarian cancer is 75%. In addition to being aggressive, serous ovarian cancer remains highly recurrent. Other factors influencing survival include age, stage at diagnosis, and presence of ascites, all of which have now been incorporated into the standard prognostic staging system. Survival rates vary substantially among races and ethnic groups. For example, African Americans, Hispanics, and Asians have significantly poorer outcomes than Caucasians.
Xb002 is currently undergoing a Phase I trial in combination with paclitaxel and carboplatin in ovarian cancer. Xb002 may be effective as an anti-cancer agent.